Folate receptor-positive circulating tumor cells might function as potential biomarkers for hepatocellular carcinoma

Figure 3 Prognostic and predictive utility of folate receptor-circulating tumor cells in hepatocellular carcinoma. A: Comparison of disease-free survival time between hepatocellular carcinoma (HCC) patients with high and folate receptor (FR)-circulating tumor cell (CTC) counts; B: Comparison of FR + CTC counts in HCC patients before any treatment and after R0 resection or conservative treatment; C: Receiver operating characteristic curves comparing the performance of FR + CTC counts between HCC patients with early recurrence and those with late recurrence. CTC: Circulating tumor cell; AUC: Area under the curve.